Appendix 3: Selected Cancer Drugs and Indications

Newly approved or newly labeled by the US Food and Drug Administration (FDA), 2014

FDA Approvals

January 2014

Dabrafenib (Tafinlar)-for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

Trametinib (Mekinist)-for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

February 2014

Ibrutinib (Imbruvica)-for the treatment of chronic lymphocytic leukemia.

April 2014

Ceritinib (Zykadia)-for the treatment of anaplastic lymphoma kinase–positive, metastatic non–small-cell lung cancer.

Mercaptopurine (Purixan)-for the treatment of acute lymphoblastic leukemia.

Ofatumumab (Arzerra)-for the treatment of chronic lymphocytic leukemia.

Ramucirumab (Cyramza)-for the treatment of metastatic, gastric or gastroesophageal junction adenocarcinoma.

Siltuximab (Sylvant)-for the treatment of multicentric Castleman disease.

July 2014

Belinostat (Beleodaq)-for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Idelalisib (Zydelig)-for the treatment of relapsed chronic lymphocytic leukemia.

August 2014

Bevacizumab (Avastin)-for the treatment of persistent, recurrent or metastatic cervical cancer.

September 2014

Pembrolizumab (Keytruda) for the treatment of unresectable or metastatic melanoma.

For additional information and an up-to-date listing of newly approved oncology drugs, visit the FDA’s website.